

COLLABORATING TO ADVANCE HEALTH EQUITY AND DIABETES AND CHRONIC KIDNEY DISEASE

WEDNESDAY, FEBRUARY 10, 2021

10:00-10:05 a.m. - Opening remarks by RADM Richardae Araojo

10:05-10:15 a.m. - Keynote Speaker: La Shawn McIver, Director, CMS Office of Minority Health

SESSION 1: 10:15 - 11:30 a.m.

Using Patient Experience Data and Community/System Approach to Inform Care, Drug Development and the Overall Research Agenda

Moderator: Chanel Whittaker (Associate Professor, UMSOP)

Panelists: Andrea Furia-Helms (Director of Patient Affairs, FDA) Richard Knight (President, AAKD Board of Directors)
Anne Bullock (Director, IHS Division of Diabetes Treatment and Prevention)
Rana Malek (Clinical Associate Professor, UMSOM)

Purpose: Leveraging patient experience data and community/system to inform care, drug development, and overall research agenda to improve patient outcomes and reduce health inequities for diverse communities with diabetes and chronic kidney disease (CKD).

LUNCH BREAK: 11:15 – 12:30 p.m.

SESSION 2: 12:30-1:45 p.m.

Diversity in Clinical Trials in Diabetes and CKD

Moderator: Christine Lee (Strategic Research Engagement Lead, OMHHE)

Panelists: Rekha Kambhampati (Physician, FDA) Andreea Lungu (Physician, FDA)
Milena Lolic (Lead Medical Officer, FDA) Jovonni Spinner (Senior Public Health Advisor, FDA)
Teisha Harris (Deputy Director and Chief Operating Officer, YCCI and Associate Director for Clinical Research, Yale School of Medicine)

Purpose: Explore barriers to diversity in clinical trials for CKD and diabetes and describe strategies to improve clinical trial diversity.

BREAK: 1:45-2:00 p.m.

SESSION 3: 2:00 - 3:00 p.m.

RWD Research in Diabetes and CKD

Moderator: Charmaine Rochester (Professor, Department of Pharmacy Practice and Science, UMSOP)

Panelists: Len Pogach (National Program Director, Diabetes and Endocrinology, VA)
Qi Liu (Senior Science Advisor, FDA)
Jenna Norton (Associate Director, Division of Kidney, Urologic, and Hematologic Diseases, NIH)
Clydette Powell (Designated National Officer, National Clinic Care Commission)

Purpose: Utilization of real-world data to inform strategies and decision making on management of diabetes and CKD.

3:00 - 3:05 p.m. - Closing remarks, OMHHE